Viatris

Viatris was formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer. By integrating the strengths of these two companies, including our global workforce of ~40,000, we aim to deliver increased access to affordable, quality medicines for patients worldwide.

Our global portfolio includes best-in-class, iconic brand name products as well as global key brands; generics, including branded and complex generics; biosimilars; and over-the-counter offerings across a wide range of therapeutic areas. We are committed to helping create healthier communities worldwide through education, outreach and better access to treatment.

Timeline

Patents

Further Resources

Title

Author

Link

Type

Date

Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Recall of One Batch of Semglee® (insulin glargine injection), 100 units/mL (U-100), 3 mL Prefilled Pens, Due to the Potential for a Missing Label in the Batch

https://newsroom.viatris.com/2022-01-18-Mylan-Pharmaceuticals-Inc-,-a-Viatris-Company,-Conducting-Voluntary-Recall-of-One-Batch-of-Semglee-R-insulin-glargine-injection-,-100-units-mL-U-100-,-3-mL-Prefilled-Pens,-Due-to-the-Potential-for-a-Missing-Label-in-the-Batch

Web

18.01.2022

Viatris Announces 9% Dividend Increase, Fourth Consecutive Quarterly Dividend

https://newsroom.viatris.com/2022-01-06-Viatris-Announces-9-Dividend-Increase,-Fourth-Consecutive-Quarterly-Dividend

Web

06.01.2022

Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease

https://newsroom.viatris.com/2022-02-03-Viatris-is-First-to-Receive-FDA-Approval-of-Generic-Restasis-R-Cyclosporine-Ophthalmic-Emulsion-0-05-to-Treat-Dry-Eye-Disease

Web

03.02.2022

Viatris to Host Virtual Investor Event and Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

https://newsroom.viatris.com/2022-02-04-Viatris-to-Host-Virtual-Investor-Event-and-Report-Fourth-Quarter-and-Full-Year-2021-Financial-Results-on-February-28,-2022

Web

04.02.2022

News

Title

Author

Date

Publisher

Description

Mylan Wins Significant Summary Judgment Rulings in Kansas EpiPen® Class Action

Viatris Inc.

June 24, 2021

www.prnewswire.com:443

/PRNewswire/ -- Viatris (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas ruled, in substantial part, in Mylan's favor on...

'When is this going to end?': US factory town devastated by jobs moving overseas

Michael Sainato

June 20, 2021

the Guardian

The Viatris plant in West Virginia has been making pharmaceuticals since 1965 - but it's closing down and laying workers off

Five pharmaceutical companies get approval to make black fungus drug

Aneesh Phadnis & Vinay Umarji

May 20, 2021

@bsindia

These developments come amid fast spread of the disease in various states and shortage of drugs to treat them.

Un año después de los confinamientos en todo el mundo por la COVID-19, un panel médico analiza el impacto de la pandemia en los pacientes con condiciones subyacentes y la necesidad de priorizar las enfermedades crónicas en el futuro

Viatris Inc.

April 20, 2021

www.prnewswire.com:443

/PRNewswire/ -- El miércoles 21 de abril, entre las 8:00 a. m. y las 9:30 a. m. hora de verano del este, el Consejo Empresarial para el Entendimiento...

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Theravance Biopharma, Inc.

February 23, 2021

www.prnewswire.com:443

/PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth quarter and...